Cargando…

JAK Inhibitors in Psoriatic Disease

Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory condition, recognized under the term Psoriatic Disease (PsD). PsD has several extracutaneous manifestations, such as inflammatory articular and entheseal involvement, leading to psoriatic arthritis (PsA), and the le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Megna, Matteo, Potestio, Luca, Ruggiero, Angelo, Cacciapuoti, Sara, Maione, Francesco, Tasso, Marco, Caso, Francesco, Costa, Luisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625379/ https://www.ncbi.nlm.nih.gov/pubmed/37927384 http://dx.doi.org/10.2147/CCID.S433367

Ejemplares similares

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
por: Megna, Matteo, et al.
Publicado: (2021)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future
por: Navarini, Luca, et al.
Publicado: (2020)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
por: Potestio, Luca, et al.
Publicado: (2023)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
por: Caiazzo, Giuseppina, et al.
Publicado: (2023)

Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis
por: Peluso, Rosario, et al.
Publicado: (2019)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Herpes Zoster and COVID-19 Vaccination: A Narrative Review
por: Potestio, Luca, et al.
Publicado: (2023)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
por: Peluso, Rosario, et al.
Publicado: (2018)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

Towards Personalized Medicine in Psoriasis: Current Progress
por: Camela, Elisa, et al.
Publicado: (2022)

Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study
por: Navarini, Luca, et al.
Publicado: (2018)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis
por: Ruggiero, Angelo, et al.
Publicado: (2021)

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
por: Camela, Elisa, et al.
Publicado: (2023)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders
por: Ruscitti, Piero, et al.
Publicado: (2021)

Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Simple clinical indicators for early psoriatic arthritis detection
por: Caso, Francesco, et al.
Publicado: (2014)

Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
por: Costa, Luisa, et al.
Publicado: (2017)

A new player in psoriatic arthritis: a JAK inhibitor
por: Sakkas, Lazaros I.
Publicado: (2017)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
por: Battista, Teresa, et al.
Publicado: (2023)

Letter to the editor regarding article “Yalici‐Armagan B, Tabak GH, Dogan‐Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID‐19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1–5”
por: Potestio, Luca, et al.
Publicado: (2021)

The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection
por: Atteno, Mariangela, et al.
Publicado: (2014)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vljdrdj76p7dd6iq6peil3vjif